Are hypertension patients taking ACEIs/ARBs at increased risk of COVID-19 complications?
A study published in JAMA Cardiology suggests that hypertension patients undergoing ACEIs/ARBs treatment are not at increased risk for negative COVID-19 outcomes. Dr. Samuel Botros M.D. discusses the recent study.
Thanks to data analysis conducted by Juyi Li, MD of Tongji Medical College in Wuhan, China — there is good news for individuals diagnosed with hypertension. Li and her colleagues uncovered, after analyzing data from 1,178 COVID-19 positive patients, that individuals with hypertension who are taking ACEIs/ARBs are not at increased risk of COVID-19 mortality.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) act as life-changing treatments for patients suffering from hypertension. In a time of COVID-19-induced chaos, Dr. Samuel Botros M.D. is happy to be able to ease some concerns that his patients with hypertension may have been experiencing.
